Valuation: Vivos Inc.

Market Cap 23.18M 20.76M 19.15M 17.33M 32.41M 2.21B 32.94M 229M 91.17M 1.16B 86.99M 85.14M 3.66B P/E 2024
-16.2x
P/E 2025 -10.2x
Enterprise Value 21.74M 19.47M 17.96M 16.25M 30.39M 2.07B 30.88M 214M 85.49M 1.08B 81.57M 79.83M 3.43B EV / Sales 2024
1,724x
EV / Sales 2025 438x
Free-Float
95.44%
Yield 2024 *
-
Yield 2025 -
1 day-2.56%
1 week-0.95%
Current month-8.60%
1 month-5.58%
3 months-21.55%
6 months-34.48%
Current year-33.67%
1 week 0.04
Extreme 0.04
0.05
1 month 0.04
Extreme 0.0391
0.05
Current year 0.04
Extreme 0.0391
0.12
1 year 0.04
Extreme 0.0391
0.12
3 years 0.04
Extreme 0.0391
0.26
5 years 0.04
Extreme 0.0391
0.26
10 years 0.01
Extreme 0.0065
1.92
Manager TitleAgeSince
Chief Executive Officer 79 14/12/2016
President 44 15/09/2025
Director of Finance/CFO 59 01/12/2018
Director TitleAgeSince
Chairman 81 14/12/2016
Director/Board Member 79 02/08/2017
Date Insider Type Main position Quantity % Market Cap. Importance
7/10/26 Issuer sale

Chairman

-385,302 100.0000%
30/9/26 Buy

Chief Executive Officer

200,000 0.0405%
16/9/26 Buy

Chairperson

25,550 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-2.56%-0.95%-42.62%-21.21% 23.18M
+0.71%+4.82%+27.02%+63.36% 260B
+1.24%+3.15%+10.73%+28.03% 165B
+1.03%+1.11%-16.52%+73.61% 154B
+0.61%-7.22%-57.44%-14.71% 61.49B
+2.90%+4.83%+14.21%+51.44% 52.9B
+0.70%+2.71%-13.09%-6.29% 52.84B
-2.35%-3.79%+8.26%+63.10% 51.46B
-0.18%+4.18%+26.50%+79.06% 51.16B
+0.67%+5.37%+39.77%+102.82% 46.85B
Average +0.10%+1.29%-0.32%+41.92% 89.57B
Weighted average by Cap. +0.45%+1.41%+7.18%+51.40%

Financials

2024 2025
Net sales 28K 25.08K 23.13K 20.93K 39.15K 2.67M 39.78K 276K 110K 1.4M 105K 103K 4.42M 68.38K 61.25K 56.5K 51.13K 95.61K 6.51M 97.16K 674K 269K 3.41M 257K 251K 10.79M
Net income -2.91M -2.61M -2.41M -2.18M -4.07M -277M -4.14M -28.69M -11.45M -145M -10.92M -10.69M -459M -3.07M -2.75M -2.53M -2.29M -4.29M -292M -4.36M -30.23M -12.06M -153M -11.51M -11.26M -484M
Net Debt -2.21M -1.98M -1.83M -1.65M -3.09M -211M -3.14M -21.81M -8.7M -110M -8.3M -8.13M -349M -1.44M -1.29M -1.19M -1.08M -2.02M -138M -2.05M -14.24M -5.68M -71.98M -5.42M -5.3M -228M
Projected Income Statement - Annual - Vivos Inc.
Logo Vivos Inc.
Vivos Inc. is a radiation oncology medical device company. The Company has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Employees
1
Date Price Change Volume
30/10/26 USD 0.0457 -2.56% 126,274
28/10/26 USD 0.0469 +6.42% 676,022
27/10/26 USD 0.0441 +0.62% 331,723
26/10/26 USD 0.0438 -0.68% 886,728
23/10/26 USD 0.0441 -4.42% 3,385,733
  1. Stock Market
  2. Stocks
  3. RDGL Stock